Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Citi sets bullish target on Summit Therapeutics shares, cites high trial success chance

EditorEmilio Ghigini
Published 05/07/2024, 05:50 AM
SMMT
-

On Tuesday, Citi initiated coverage on Summit Therapeutics plc (NASDAQ:SMMT) with a Buy rating and a price target of $7.00 for the shares. The firm's analysis suggests that Summit's leading drug candidate, ivonescimab, has a strong potential to change the treatment dynamics for non-small cell lung cancer (NSCLC).

According to Citi, the drug is well-positioned based on its mechanism-of-action, its advanced stage in development, and its potential to outperform existing treatments for NSCLC.

Citi's coverage notes that Phase 1/2 clinical trial data for ivonescimab in first-line squamous NSCLC and second-line EGFR-mutated NSCLC has shown efficacy that exceeds current standard-of-care benchmarks.

Summit Therapeutics is currently conducting two global Phase 3 trials, named HARMONi and HARMONi3, targeting second-line EGFR-mutated and first-line squamous NSCLC, respectively. Success in these trials could significantly broaden ivonescimab's use across various solid tumor indications.

The firm's proprietary Clinical Trial Simulator indicates that the HARMONi trial has approximately an 80% chance of success in terms of progression-free survival (PFS), while the HARMONi3 trial has about a 60% chance of success in overall survival (OS). These high probabilities of trial success underscore the confidence in ivonescimab's clinical development.

Citi also believes that ivonescimab could present a more favorable clinical benefit/risk profile in the second-line EGFR-mutated NSCLC setting compared to the combination of amivantamab and chemotherapy.

Furthermore, the first-line squamous NSCLC market, which is substantially larger but less competitive, is currently dominated by the combination of Keytruda and chemotherapy. Ivonescimab stands out as one of the few late-stage assets targeting this market exclusively.

The initiation of coverage by Citi also comes with a 90-day Catalyst Watch, signaling that the investment firm is closely monitoring the upcoming developments and potential market-moving events related to Summit Therapeutics and ivonescimab.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.